Physician profile
Lane Williams
NPI 1548202500
$1,594.23
in general payments reported to CMS, 2019-2025
24 companies · $451 in 2025
The $451 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $31.97 · 2021: $221 · 2022: $282 · 2023: $196 · 2024: $308 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $954.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $242.76 | 2024-2025 | Zurzuvae |
| Abbvie INC. | $162.69 | 2019-2022 | |
| Daiichi Sankyo INC. | $153.76 | 2020-2024 | Injectafer |
| Glaxosmithkline, LLC. | $115.14 | 2022-2025 | Shingrix, Bexsero |
| Exeltis, USA INC. | $107.25 | 2021-2025 | Slynd, Solosec |
| Hologic Sales and Service, LLC | $106.86 | 2022-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Aptima, Novasure |
| Bayer Healthcare Pharmaceuticals INC. | $101.62 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.44 | 2022-2025 | Trintellix |
| Organon LLC | $80.99 | 2022-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $80.72 | 2021-2025 | |
| Coopersurgical, INC. | $55.89 | 2023-2024 | Fisherbrand Disposable Liquid Infant Heel Warmer, Paragard T 380a |
| Allergan, INC. | $41.93 | 2019-2020 | |
| Pfizer INC. | $41.06 | 2023-2024 | |
| Amgen INC. | $40.39 | 2019-2025 | Evenity |
| Pacira Pharmaceuticals Incorporated | $37.01 | 2023-2024 | Exparel, Iovera |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $20.30 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.23 | 2022 | |
| Lilly USA, LLC | $16.97 | 2025 | Zepbound |
| Sumitomo Pharma America, INC. | $15.32 | 2025 | Myfembree |
| Avion Pharmaceuticals | $14.94 | 2021 | |
| Millicent US INC | $13.53 | 2025 | Intrarosa, Femring |
| Amag Pharmaceuticals, INC. | $13.32 | 2019 | |
| Evofem Biosciences, INC. | $11.56 | 2021 | |
| Merck Sharp & Dohme LLC | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lane Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.